ArticlePharmacoEconomics2024

Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.

Anita J Brogan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.